A new disclosure filed with the U.S. House of Representatives shows that Rep. Julia Letlow purchased shares of AbbVie Inc. (ABBV) common stock, according to a Periodic Transaction Report submitted under the STOCK Act. The transaction is logged in our system as a congress buy signal.
The report lists the transaction date as October 23, 2024, with the purchase made personally by Rep. Letlow rather than a spouse or dependent. The disclosed amount falls between $1,001 and $15,000, the smallest reporting bracket used under the STOCK Act’s tiered range system. The holding was made through Merrill Lynch Investment Account #025.
What stands out most in this filing isn’t the size of the trade but the timing of its disclosure. The STOCK Act requires members of Congress to report transactions like this within 45 days. This report was filed 292 days after the purchase date, well past that window. We’re noting this delay as a matter of public record, without speculating on the cause.
What the Filing Does and Doesn’t Show
A Periodic Transaction Report like this one confirms that a trade occurred, the approximate dollar range, the date, and the account used. It does not explain why the purchase was made, whether it relates to any legislative activity, or whether it represents a small piece of a larger portfolio. AbbVie is a large, widely held pharmaceutical company, and a purchase in the $1,001–$15,000 range is a modest position relative to the amounts often seen in these disclosures.
For readers who follow congressional stock trades as a category — whether searching for a running list of trades tied to well-known lawmakers, or simply trying to understand how disclosure timing works — this filing is a useful example of both the mechanics and the limits of STOCK Act reporting. Filings are self-reported by members of Congress, and enforcement of the 45-day deadline has been inconsistent, which is why late filings like this one surface periodically across both parties.
If you’re interested in how institutional money managers disclose their own portfolio moves on a different filing schedule, our coverage of Defilade Capital Management, L.P.’s quarterly 13F activity offers a comparison point — those filings are required quarterly rather than per-transaction, and cover institutional rather than individual accounts.
We’ll continue tracking future Periodic Transaction Reports tied to Rep. Letlow’s Merrill Lynch account as they’re filed, including whether any additional AbbVie activity or other holdings appear in subsequent disclosures.